<DOC>
	<DOCNO>NCT00851604</DOCNO>
	<brief_summary>The purpose study determine whether monitoring level Serological Markers ProGRP , CgA , NSE Pyruvate Kinase M2 effective Evaluation Diagnosis , Monitoring Therapeutic Effects Predicting response somatostatin analogues Patients Malignant Neuroendocrine Tumors .</brief_summary>
	<brief_title>ProGRP , CgA , NSE TUM2-PK Patients With Neuroendocrine Tumors</brief_title>
	<detailed_description>Assessment anatomical spread disease progression neuroendocrine tumor patient become essential part disease management , sometimes many patient difficult measure . Therefore , evaluation serum marker could represent useful tool monitoring course disease response patient therapy palliative treatment.Clinical data considers CgA NSE available today blood biomarkers neuroendocrine tumors.Until usefulness serum ProGRP clinical tumor marker evaluate mainly Small Cell Lung Carcinoma , role management NE tumor elucidated.Available literature limit data suggests ProGRP may potential tumor marker NE tumor . Pyruvate kinase type M2 key glycolytic regulator tumor cells.It catalyze dephosphorylation phosphoenolpyruvate pyruvate ATP production.The dimeric form enzyme ( TUM2-PK ) detect blood patient different cancers.High TUM2-PK expression suggest important element tumor cell metabolism adaptation inadequate oxygen nutrient supply.Recently , show somatostatin structural analogue pass cell membrane actively bind cytosolic TUM2-PK . In response bind TUM2-PK translocates nucleus induce program cell death . It suggest TUM2-PK enzyme may contribute significantly response neuroendocrine tumor somatostatin analogue .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>The patient diagnosis neuroendocrine tumor therapy approach participate study . Older 18 year old Patients agree participate receive detailed explanation sign inform consent form . Pregnant woman Coexistence another primary malignant tumor neuroendocrine tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>ProGRP</keyword>
	<keyword>CgA</keyword>
	<keyword>NSE</keyword>
	<keyword>TUM2-PK</keyword>
	<keyword>Neuroendocrine Tumors</keyword>
</DOC>